TWI899184B - 治療或抑制急性骨髓性白血病復發之化合物 - Google Patents

治療或抑制急性骨髓性白血病復發之化合物

Info

Publication number
TWI899184B
TWI899184B TW110109254A TW110109254A TWI899184B TW I899184 B TWI899184 B TW I899184B TW 110109254 A TW110109254 A TW 110109254A TW 110109254 A TW110109254 A TW 110109254A TW I899184 B TWI899184 B TW I899184B
Authority
TW
Taiwan
Prior art keywords
mmol
pyrrolo
pyrimidin
amino
phenoxyphenyl
Prior art date
Application number
TW110109254A
Other languages
English (en)
Chinese (zh)
Other versions
TW202200583A (zh
Inventor
涵誠 吳
志雄 葉
丁克家
Original Assignee
國立研究開發法人理化學研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立研究開發法人理化學研究所 filed Critical 國立研究開發法人理化學研究所
Publication of TW202200583A publication Critical patent/TW202200583A/zh
Application granted granted Critical
Publication of TWI899184B publication Critical patent/TWI899184B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW110109254A 2020-03-16 2021-03-16 治療或抑制急性骨髓性白血病復發之化合物 TWI899184B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2020/079464 2020-03-16
PCT/CN2020/079464 WO2021184154A1 (en) 2020-03-16 2020-03-16 Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Publications (2)

Publication Number Publication Date
TW202200583A TW202200583A (zh) 2022-01-01
TWI899184B true TWI899184B (zh) 2025-10-01

Family

ID=77767943

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110109254A TWI899184B (zh) 2020-03-16 2021-03-16 治療或抑制急性骨髓性白血病復發之化合物

Country Status (15)

Country Link
US (1) US11963960B2 (cg-RX-API-DMAC7.html)
EP (1) EP4121430A4 (cg-RX-API-DMAC7.html)
JP (1) JP7744358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102990081B1 (cg-RX-API-DMAC7.html)
CN (1) CN115298180B (cg-RX-API-DMAC7.html)
AR (1) AR121570A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020436612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018345A2 (cg-RX-API-DMAC7.html)
CA (1) CA3168988A1 (cg-RX-API-DMAC7.html)
IL (1) IL296296A (cg-RX-API-DMAC7.html)
MX (1) MX2022011407A (cg-RX-API-DMAC7.html)
PE (1) PE20230461A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552169A1 (cg-RX-API-DMAC7.html)
TW (1) TWI899184B (cg-RX-API-DMAC7.html)
WO (2) WO2021184154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
AU2021289345A1 (en) * 2020-06-08 2023-01-19 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
CN114075190A (zh) 2020-08-20 2022-02-22 北京诺诚健华医药科技有限公司 杂环类btk抑制剂
CN113861179A (zh) * 2021-10-22 2021-12-31 上海应用技术大学 一种新型flt3激酶抑制剂及其合成与应用
WO2025124429A1 (zh) * 2023-12-11 2025-06-19 北京康辰药业股份有限公司 芳香胺化合物及其药物组合物、应用
WO2025151010A1 (ko) * 2024-01-11 2025-07-17 주식회사 펠레메드 신규한 피롤로트리아진 유도체 및 이의 용도
KR20250157634A (ko) 2024-04-29 2025-11-05 대한민국(질병관리청 국립보건연구원장) Bax 활성제를 유효성분으로 포함하는 항-hiv-1 조성물

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041525A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
WO2002080926A1 (en) 2001-03-22 2002-10-17 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US20030153752A1 (en) * 1998-09-18 2003-08-14 Hirst Gavin C. Pyrrolopyrimidines as therapeutic agents
WO2008121742A2 (en) * 2007-03-28 2008-10-09 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2014017659A1 (ja) * 2012-07-27 2014-01-30 独立行政法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
CN105481862A (zh) * 2015-01-21 2016-04-13 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
WO2018052120A1 (en) * 2016-09-15 2018-03-22 Riken A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ510588A (en) 1998-09-18 2003-08-29 Abbott Gmbh & Co Pyrrolopyrimidines as protein kinase inhibitors
KR20020088406A (ko) * 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
MXPA03008560A (es) * 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
WO2005074603A2 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
BRPI0619146A2 (pt) 2005-12-02 2011-09-13 Bayer Pharmaceuticals Corp derivados de 4-amino-pirroltriazina substituìda úteis no tratamento de disordens e doenças hiperproliferativas associadas com angiogênesis
US7772231B2 (en) 2005-12-29 2010-08-10 Abbott Laboratories Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
USRE48175E1 (en) * 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
WO2016019237A2 (en) 2014-07-31 2016-02-04 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
GB201508747D0 (en) 2015-05-21 2015-07-01 Univ Edinburgh Compounds
CN118027041A (zh) * 2019-05-31 2024-05-14 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
AU2020301399B2 (en) 2019-06-24 2025-12-18 Dana-Farber Cancer Institute, Inc. HCK degraders and uses thereof
CN114746095B (zh) 2019-10-08 2025-01-24 达纳-法伯癌症研究所有限公司 Hck作为myd88突变疾病的治疗靶点
MX2022008148A (es) * 2020-01-02 2022-07-21 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de btk.
AU2020436612A1 (en) 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998041525A1 (en) * 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
US20030153752A1 (en) * 1998-09-18 2003-08-14 Hirst Gavin C. Pyrrolopyrimidines as therapeutic agents
WO2002080926A1 (en) 2001-03-22 2002-10-17 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
WO2008121742A2 (en) * 2007-03-28 2008-10-09 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2014017659A1 (ja) * 2012-07-27 2014-01-30 独立行政法人理化学研究所 急性骨髄性白血病の治療又は再発抑制剤
CN105481862A (zh) * 2015-01-21 2016-04-13 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途
WO2018052120A1 (en) * 2016-09-15 2018-03-22 Riken A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
期刊 Koda Y, et al. "Identification of pyrrolo [2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors" Bioorganic & medicinal chemistry letters 27(22): Elsevier 2017; 4994-4998
期刊 Koda Y, et al. "Identification of pyrrolo [2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors" Bioorganic & medicinal chemistry letters 27(22): Elsevier 2017; 4994-4998;期刊 Yuki H, et al. "Activity cliff for 7-substituted pyrrolo-pyrimidine inhibitors of HCK explained in terms of predicted basicity of the amine nitrogen" Bioorganic & medicinal chemistry 25(16): Elsevier 2017; 4259-4264 *
期刊 Yuki H, et al. "Activity cliff for 7-substituted pyrrolo-pyrimidine inhibitors of HCK explained in terms of predicted basicity of the amine nitrogen" Bioorganic & medicinal chemistry 25(16): Elsevier 2017; 4259-4264

Also Published As

Publication number Publication date
CN115298180A (zh) 2022-11-04
PH12022552169A1 (en) 2024-01-29
JP2023518035A (ja) 2023-04-27
EP4121430A1 (en) 2023-01-25
CA3168988A1 (en) 2021-09-23
WO2021184154A1 (en) 2021-09-23
AU2021239828A1 (en) 2025-04-03
KR102990081B1 (ko) 2026-07-10
BR112022018345A2 (pt) 2022-11-08
AR121570A1 (es) 2022-06-15
WO2021188417A1 (en) 2021-09-23
US20210299128A1 (en) 2021-09-30
TW202200583A (zh) 2022-01-01
JP7744358B2 (ja) 2025-09-25
AU2020436612A1 (en) 2022-09-01
AU2021239828B2 (en) 2025-06-26
US11963960B2 (en) 2024-04-23
PE20230461A1 (es) 2023-03-14
IL296296A (en) 2022-11-01
CN115298180B (zh) 2025-06-10
KR20220154164A (ko) 2022-11-21
MX2022011407A (es) 2022-10-13
EP4121430A4 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
CN115298180B (zh) 治疗或抑制急性髓细胞白血病复发的化合物
TWI811353B (zh) 作為parp7抑制劑的嗒酮
CN102548557B (zh) 用于降低β-淀粉状蛋白生成的化合物
CN106061973B (zh) 吡咯并[2,3-d]嘧啶基、吡咯并[2,3-b]吡嗪基和吡咯并[2,3-d]吡啶基丙烯酰胺
TWI498325B (zh) 3-取代吡唑及其用途
CN104470925B (zh) 作为激酶抑制剂的咪唑并三嗪甲腈
CN105732636A (zh) 杂芳化合物及其在药物中的应用
KR20180015160A (ko) Brk 저해 화합물
TWI596095B (zh) Dihydropyridazine-3,5-dione derivatives
CN105164114A (zh) C-连接的杂环烷基取代的嘧啶类和它们的用途
CN102827170A (zh) 治疗活性组合物和它们的使用方法
CN105939997A (zh) 作为dlk抑制剂的吡唑衍生物及其用途
CN103328451B (zh) 降低β-淀粉样物质生成的化合物
US20240092761A1 (en) Quinazoline compounds and methods of use
JP2019501971A (ja) 縮合四環式の化合物、組成物及びその使用
CN120981466A (zh) 作为egfr抑制剂的大环氨基吡啶化合物
HK40083594A (en) Compounds for treating or inhibiting recurrence of acute myeloid leukemia
WO2025153712A1 (en) Tricyclic compounds, preparation thereof and therapeutic uses as erk5 inhibitors
HK40117941A (en) Pharmaceutical composition for treating cancer, comprising anticancer agent and novel compound having inhibitory activity with respect to prostaglandin e2 receptors
HK1242689A1 (en) Heterocyclic acrylamides
HK1209114B (en) 3-substituted pyrazoles and use as dlk inhibitors
HK40006173B (en) Fused quadracyclic compounds, compositions and uses thereof
HK1228913A1 (en) Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
HK1124603A (en) Pyridazinone derivatives used for the treatment of pain
HK1244486A1 (zh) 三环dlk抑制剂及其用途